

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Initial treatment strategies.

Treatment	Entire cohort (N=727)	Decade 1 (1980-1989) (N=79)	Decade 2 (1990-1999) (N=163)	Decade 3 (2000-2009) (N=254)	Decade 4 (2010-2017) (N=231)
Watchful waiting (%)	110 (15)	2 (3)	5 (3)	34 (13)	69 (30)
R-CHOP (%)	174 (24)	0	0	92 (36)	82 (35)
R-CVP (%)	43 (6)	0	0	25 (10)	18 (8)
Other R-containing regimens (%)	45 (6)	0	0	25 (10)	20 (9)
Single-agent rituximab (%)	48 (7)	0	0	8 (3)	40 (17)
CHOP-like (%)	199 (27)	50 (63)	122 (75)	27 (11)	0
Fludarabine-based (%)	34 (5)	0	3 (2)	31 (12)	0
Other treatments/unknown (%)	74 (10)	27 (34)	33 (20)	12 (5)	2 (1)

Most used treatment modality in each decade is highlighted in bold.

CVP, cyclophosphamide, vincristine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab.